Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the Institution or an Investigator may publish or otherwise publicly disclose the results of the Trial or the treatment of any Subject participating in the Trial for internal research and educational purposes, subject, however, to the following conditions and compliance with Section 7(c) above:
Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the Institution or an Investigator may publish or otherwise publicly disclose the results of the Trial or the treatment of any Subject participating in the Trial for internal research and educational purposes, subject, however, to the following conditions and compliance with Section 7(c) above: (a) Postup při publikování. Po dokončení Klinického hodnocení a vyhodnocení výsledků nebo po upuštění od Klinického hodnocení mohou Zdravotnické zařízení nebo Zkoušející publikovat nebo jinak zveřejnit výsledky Klinického hodnocení nebo léčby kteréhokoliv Subjektu zapojeného do Klinického hodnocení pro účely interního výzkumu a vzdělávání, nicméně musí při tom být dodrženy následující podmínky a požadavky čl. 7(c) výše:
(i) A copy of such disclosure shall be given to Biogen for review, with reference to this paragraph, at least sixty (60) days prior to delivery to any other party. (i) kopie takto zveřejňovaných materiálů musí být s odkazem na tento odstavec předložena ke kontrole společnosti Biogen nejméně šedesát (60) dnů před jejich doručením jakékoliv jiné straně.
(ii) If Biogen gives notice during such period that it intends to file patent applications relating to matters contained in such disclosure, disclosure shall be delayed for up to an additional ninety (90) days from such notice to permit such filings. (ii) pokud společnost Biogen zašle během této doby oznámení, že má ve vztahu k záležitostem obsaženým v takových materiálech v úmyslu podat přihlášky na registraci patentů, bude zveřejnění odloženo až o dalších devadesát (90) dnů od takového oznámení, aby mohly být podány příslušné přihlášky.
(iii) As the Trial is part of the Study, no disclosure shall be made until results from all centres have been received and analysed, or the Study has been abandoned at all centres. If a committee of investigators is formed for publication of results of the Study, any separate publication by the Institution or the Investigator shall be delayed until the initial publication by the committee or a determination is made by the committee not to make such publication. If the committee does not produce an initial publication within twelve (12) months after the results (iii) jelikož Klinické hodnocení tvoří součástí Studie, nesmí být žádné informace zveřejněny, dokud nebudou k dispozici výsledky ze všech zařízení a nebude provedena jejich analýza nebo dokud nedojde k upuštění od...
Publication Procedure. The default arrangement is “assumed permission”. If the publishing party does not receive a written objection from the reviewing party within [45]/[60]/[90] days of submission of notification of publication then permission to publish will be deemed to have been given. The ZonMw Terms and Conditions Governing Grants of ZonMw allows for a maximum period of 90 days.
1. A Party wishing to publish in written form, oral presentation or make public in any other form, information relating to the Background, Results or any other information regarding the Project – confidential or not– will submit in writing to the Project Leader the intended publication 45 days before the intended publication date or before the date of submission for disclosure to review the publication.
2. The intended publication will clearly state the intended publication date.
3. The Project Leader will promptly make the intended publication available to the other Parties.
4. The intended publication is Confidential Information and as such protected in the manner this agreement provides for.
5. The Parties will have 45 days to review the intended publication.
6. The Parties can, by giving written Notice to the Project Leader, raise an objection with regard to the inclusion of their Confidential Information or may request a delay for a maximum of 90 days after receipt of the written Notice by the Project Leader, in order to seek patent or similar protection for the Results that are proposed to be published.
7. The publishing party will remove any Confidential Information. Any other comments will be considered by the author(s) in good faith. The author is under no obligation to incorporate such comments.
Publication Procedure. At the end of the research, the publishable part of the Results will be described in the final report as defined under section 4.4.3. Review of publications Any publication or communication, whether written or oral, in connection with Result is required to be submitted to the Collaborative Board. To this end, the full text of the proposed publication or communication shall be submitted to the Collaborative Board. If the Collaborative Research Project has established a secure web site, then the full text can be submitted through it. Each member of the Collaborative Board will have the possibility to appoint one or several internal expert(s) to assess the content of the publication. Each member of the Collaborative Board will have one (1) calendar month from the date of submission of the publication to object to it it in writing to the Chairman. Beyond this period, if no objection has been received consent shall be deemed to have been given. This obligation, nonetheless, should not prevent the application of a Patent in accordance with the provisions of this Consortium Agreement, nor should it unnecessarily prevent a possible commercial use.
Publication Procedure. On completion of the
Publication Procedure. On completion of the Trial and evaluation of the results, or abandonment of the Trial, respectively, the (a) Postup při publikování. Po dokončení Klinického hodnocení a vyhodnocení výsledků nebo po upuštění od Klinického hodnocení
Publication Procedure and the IPRs Guidelines (D9.1). Scientific communities Industries and innovation centres Worldwide SSSA INRCA XXXXX ORU XXXX UOP RT
Publication Procedure. Scientific communities Industries and innovation centres Worldwide SSSA INRCA XXXXX ORU XXXX UOP RT Conference Date Location Participants 8th World Demographic & Ageing Forum August 27-30, 2012 St.Gallen, Switzerland 500 participants RO-MAN 2012 September 9, 2012 Paris, France 300 participants AAL Forum 2012 September 24-27, 2012 Eindhoven, Netherlands 1200 participants3 IROS 2012 October 7-12, 2012 Vilamoura Algarve, Portugal – 1500 exhibitors papers accepted submitted) / 790 (2500 foritaal2012 Forum October 17- 19, 2012 Parma, Italy 150 participants SIGG (Società Italiana di Gerontologia e Geriatria) November 21- 24,2012 Milano, Italy 1300 participants papers submitted4 / 350 HRI 2013 8th International conference on human-robot interaction March 3-6, 2013 Tokyo, Japan ICRA 2013 May 6 – 10, 2013 Karlsruhe, Germany 1800 participants papers accepted / 850 IAGG 2013 – “Digital Ageing: New Horizon for Health Care and Active Aging” June 23-27, 2013 Seoul, Korea It comprises 73 national organizations in 65 countries with a combined membership of 45,100 EMBC 2013 July 3-7, 2013 Osaka, Japan 1900 exhibitors AAAI-13 – 27th AAAI Conference on Artificial Intelligence July 14–18, 2013 Bellevue, Washington, USA 1000 papers submitted 3 About AAL Forum Community 4 Bollettino SIGG IROS 2013 November 3- 7, 2013 Tokyo, Japan 1500 exhibitors papers accepted / 790 ICRA 2014 May 5-10, 2014 Hong China Kong, 1800 participants papers accepted / 850 IFA 12th Global conference on ageing: Health, Security and Community June 10-13, 2014 Hyderabad, India 900 participants5 14th ICCHP - International Conference on Computers Helping People with Special Needs July 09-11, 2014 Université Paris 0, Xx. Xxxxx, Xxxxxx Biorob 2014 Brazil 500 participants papers submitted / 400 Health 2.0 (multiple conferences) IAS-13 – 13th International Conference on Intelligent Autonomous System ISG*ISARC2014 Conference Gerontechnology 9th World of 2014 450 participants papers submitted6 / 300 Appendix B and the website will collect the updated list of publication of the Robot-Era Project.
Publication Procedure. The management of patentable solutions is based on the IPR agreement Scientific communities Industries and innovation centres Worldwide SSSA ORU UHAM UOP MLAB ST-I RT XxX
4 . 2 S p e c i a l i s s u e s Proposals of special issues will be submitted starting from the beginning of 2013 in order to publish the special issues within the end of the project. In the “Dissemination activities per partner” paragraph, the steps of a special issue submission procedure7 are specified. Planned Description Target group/s Audience Partner(s) 5 IFA 11th Global Conference on Ageing - Ageing Connects 6 IAARC Newsletter 2012
Publication Procedure.
1. A Party wishing to publish in written form, oral presentation or make public in any other form, information relating to the Background, Results or any other information regarding the Project – confidential or not– will submit in writing to the Project Leader the intended publication 45 days before the intended publication date or before the date of submission for disclosure to review the publication.
2. The intended publication will clearly state the intended publication date.
3. The Project Leader will promptly make the intended publication available to the other Parties.
4. The intended publication is Confidential Information and as such protected in the manner this agreement provides for.
5. The Parties will have 45 days to review the intended publication.
6. The Parties can, by giving written Notice to the Project Leader, raise an objection with regard to the inclusion of their Confidential Information or may request a delay for a maximum of 90 days after receipt of the written Notice by the Project Leader, in order to seek patent or similar protection for the Results that are proposed to be published.
7. The publishing party will remove any Confidential Information. Any other comments will be considered by the author(s) in good faith. The author is under no obligation to incorporate such comments.
